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Antipyrine kinetics in liver disease and 
liver transplantation 
Antipyrine kinetics were studied in seven normal subjects, 10 patients'with liver disease, and 13 clinically 
stable patients who received a liver transplant. Five patients were studied both before and after liver 
transplantation. Antipyrine concentrations in saliva after oral dosing were measured by HPLC. The 
antipyrine tl/2 was significantly longer (P < 0.05) in patients with liver disease than in patients undergoing 
liver transplantation and normal subjects. Antipyrine clearance was not significantly different between 
patients undergoing liver transplantation and normal subjects, but it was significantly reduced (P < 0.05) 
in patients with liver disease. In five patients who were studied before and after liver transplantation, 
there was a significant (P < 0.05) increase in the antipyrine clearance and a marked reduction in its tl/2 
after liver transplantation. These results indicate that liver transplantation improves the drug metabolizing 
ability of patients with liver disease and that the oxidative metabolizing capacity of the liver in clinically 
stable patients after liver transplantation is similar to that of normal subjects. (CLIN PIiAR.M.ACOL THER 
1986;39:372-7.) 
Mehul U. Mehta, M.S., Raman Venkataramanan, Ph.D., 
Gilbert J. Burckart, Pharm.D., Richard J. Ptachcinski, Pharm.D., 
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Liver disease alters the absorption and disposition of 
a variety of drugs. 1.2 Liver transplantation is considered 
to be an effective therapeutic option in certain liver 
diseases such as biliary atresia, sclerosing cholangitis, 
alcoholic cirrhosis, and primary biliary cirrhosis and in 
certain metabolic disorders such as <XI-antitrypsin de-
ficiency.3,4 After liver transplantation, patients receive 
a number of drugs including immunosuppressants, an-
tihypertensives, antivirals, antifungals, and antibiotics. 
However, very little is known about the drug metabo-
lizing capacity in patients after successful liver trans-
plantation. 
Our primary objective was to determine the oxidative 
metabolizing capacity of the liver in patients after liver 
transplantation and to compare this with normal subjects 
and patients with liver disease. We also compared ox-
idative drug metabolizing capacity before and after liver 
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transplantation in the same patient by determining an-
tipyrine kinetic parameters. 
METHODS 
All participants gave informed, written consent be-
fore entering the study. Participants were nonsmokers 
and refrained from alcohol consumption for at least 1 
week before and during the study. Biochemical profiles 
including albumin, total protein, bilirubin (total and 
direct), SOOT, SOFT, )I-guanosine triphosphate ()I-
OTP), and alkaline phosphatase levels were determined 
before the study. Studies were conducted in seven nor-
mal subjects (four men and three women), 10 patients 
with liver disease (seven men and three women), and 
13 patients (eight men and five women) who were clin-
ically stable (total bilirubin <2.0 mg/dl) after liver 
transplantation. In all of the latter patients the study 
was conducted 1 to 2 months after transplantation, ex-
cept in one patient who was studied 7 months after 
transplantation. 
Before drug dosing blank saliva and urine samples 
were collected from all participants. After an overnight 
fast, antipyrine (600 mg) was taken by mouth with 200 
rnl water. Serial saliva samples (2.0 ml) were collected 
2,3,6,9, 12,24,30, and 36 hours after drug dosing 
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Table I. Characteristics of the participants 
Bilirubin 
Body Total (mgldl) Alkaline 
Participant Age weight Albumin protein SGOT SGPT '1-GTP phosphatase 
No. (vr) Sex (kg) ( gmld/) (gmldl) Total Direct (lUlL) (lUlL) (lUlL) (lUlL) 
Nom1al subjects 
1 28 M 71.0 4.5 7.5 0.6 0.1 40 27 33 93 
2 33 M 51.0 4.5 7.5 1.5 0.5 33 20 22 97 
3 27 M 72.5 4.9 7.6 0.7 0.2 22 14 8 60 
4 35 M 72.7 4.5 7.9 0.8 0.2 38 16 12 74 
5 24 F 62.0 
6 23 F 59.0 4.7 7.8 1.3 0.3 19 21 10 46 
7 25 F 56.8 4.7 7.5 0.7 0.3 40 14 10 37 
X 27.9 63.8 4.6 7.6 0.9 0.3 32 19 16 69 
±SD 4.6 8.6 0.2 0.2 0.4 0.2 9 5 10 25 
Patients with liver disease 
8 23 M 74.0 1.9 6.1 5.4 1.0 35 28 21 101 
9 22 F 73.0 3.1 7.4 3.8 1.9 42 35 180 466 ~TD 10 37 M 84.6 2.4 5.5 13.1 9.1 127 79 156 217 
11 19 M 56.6 2.9 5.3 0.9 0.4 47 23 441 286 
12 46 M 73.4 3.3 6.3 3.5 1.2 86 55 55 205 .-
-13 38 F 47.2 5.0 3.7 140 162 746 3635 ~ 
.;:::t 14 57 F 86.0 2.2 0.6 121 25 219 101 '1> 
15 33 M 72.0 3.0 6.5 16.6 10.0 254 161 148 240 K~ 
16 44 M 100.0 2.6 6.3 5.7 4.5 141 51 256 264 
.-.( 
17 20 M 71.7 3.4 6.2 1.1 0.3 26 44 174 129 (:) ~;"~~ 
X 33.9 73.9 2.8 6.2 5.7 3.3 102 66 239 564 ;:! .,,.. ...... 
±SD 12.8 14.8 0.5 0;6 5.2 3.6 70 53 212 1084 ftDy~ 
Patients after liver transplantation :'Jl: ~K 
8* 24 M 65.9 2.8 5.7 1.0 0.5 21 27 102 78 D~D"~ 9* 23 F 64.7 3.7 6.2 1.6 0.9 29 64 111 108 :D~: 
10* 37 M 61.5 3.1 5.8 1.4 1.0 59 25 86 103 ~~~ 
11* . 19 M 56.5 2.8 5.4 0.8 0.4 27 16 357 257 ,r'''>;; t\A"':' ~;K ; . "" 12* 46 M 70.3 2.8 5.4 1.0 0.5 13 14 38 44 ...... , : ' D~~ 
18 33 F 50.0 3.0 5.5 0.8 0.7 22 23 71 147 
19 26 F 51.8 3.7 6.5 1.5 1.1 32 37 228 225 ':1 .. 
20 23 F 57.2 2.4 4.9 1.0 0.9 33 60 86 212 ' K-:~K: 
21 26 F 46.0 3.4 5.8 1.2 1.0 12 32 173 74 ;'-" >lJ" 
22 33 F 49.1 3.8 6.0 0.7 0.4 23 117 75 50 -:->-~l~ 
23 17 M 88.3 3.8 6.4 1.6 0.5 14 28 33 55 ;:K::~; 
24 48 F 63.9 2.9 8.1 1.3 0.9 26 42 79 209 
25 45 F 57.2 3.8 5.8 1.1 0.7 25 33 46 114 
X 30.8 60.2 3.2 6.0 1.2 0.7 26 40 114 129 
±SD 10.5 11.1 0.5 0.8 0.3 0.3 12 28 91 74 
M = Male; F = female . 
• Also studied before transplantation as part of the liver disease group. 
in all participants. Additional samples were collected dure of Campbell et a1. 5 Saliva (1.0 ml) was pipetted 
at 48 and 72 hours in patients with liver disease. Sal- into 1.5 ml polypropylene vials, which were centrifuged 
ivation was stimulated by having the person chew on at 15,600 x g for 5 minutes. The clear supernatants 
a piece of parafilm. Urine was collected for 72 hours. (100 to 200 J.Ll) were pipetted into new vials to which 
All salivary and urinary samples were stored at - 20° 50 J.Ll phenacetin solution in 5% methanol (12.5 J.Lgl 
C until analyzed for unchanged antipyrine. Antipyrine ml) and l.0 ml methanol were added. The vials were 
was quantitated by modifications of the HPLC proce- mixed on a vortex for 20 seconds and centrifuged for 
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5 minutes. The clear supernatant (100 to 200 fLl) was 
then injected onto the column. Before analysis, urine 
samples were centrifuged at 2000 x g for 5 minutes. 
One hundred microliters of a phenacetin solution in 5% 
methanol (0.1 mg/ml) was added to 1 ml of the clear 
supernatant and the mixture was shaken with 10 ml 
methylene chloride for 5 minutes. The resultant mixture 
was centrifuged at 2000 x g for 5 minutes, after which 
the aqueous layer- was removed and the organic layer 
was evaporated under a stream of nitrogen. The residue 
was dissolved in 1.0 ml mobile phase and 100 fLl of 
this solution was injected onto the column. 
Samples were chromatographed at ambient temper-
ature (21 0 to 240 C) on a 25 cm x 4 mm id stainless 
steel column packed with fL-Bondapak C-18 (10 fLm; 
Waters Associates Inc.) fitted with a guard column of 
the same packing material. The mobile phase was ace-
tonitrile and acetic acid (1 % in water; 25 : 75) at a flow 
rate of 1.0 mlImin. Retention times for antipyrine and 
phenacetin were 6 .and 8 minutes, respectively. The 
instruments used consisted of a model M-45 pump, a 
model U6K injector, and a model 441 fixed wavelength 
detector from Waters Associates Inc. Ultraviolet ab-
sorption was monitored at 254 nm. Peak heights were 
measured by a Hewlett-Packard Instruments integrator 
model 3390A and the peak height ratios were plotted 
against known concentrations to obtain a s~dard 
curve. 
The saliva antipyrine AUC from time zero to infinity 
and the elimination rate constant (X.) from the terminal 
linear segment of the concentration-time curve were 
obtained by NONLIN '74. 6 Because antipyrine is rap-
idly and completely absorbed from the gastrointestinal 
tract,7 it was assumed that bioavailability was 100% 
and that the absorption rate constant was much greater 
than the x.. Antipyrine clearance (CL) was calculated 
as: CL = Dosel AUC, and the apparent volume of dis-
tribution (V...J was calculated as: Varea = CLiAz' 
In most of the participants, analysis of the saliva 
samples revealed that urine was collected for approxi-
mately 7 tl/2S. However, because of the long tl/2 of an-
tipyrine, urine collection in patients with liver disease 
was carried out only for about 2.5 tl/2S. Based on the 
amount of antipyrine excreted unchanged, the duration 
of urine collection, and the antipyrine Au the amount 
of antipyrine excreted unchanged up to infinity was 
calculated with standard pharmacokinetic equations. 8 
Normality of the data obtained was tested by the Wilk-
Shapiro test. Homogeneity of variances was tested by 
the F ratio test; the data analyzed were compared be-
tween groups by Student's t test. A P value <0.05 was 
considered to be significant. 
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RESULTS '. J 
Table I shows the demographic and biochemiCal pro- . . •. 1 .. ·. 
file of all the participants. Average age and body weight 
were similar in each of the groups studied. Comparison 
of the measures of hepatic injury obtained (such as ·1 
bilirubin, SGOT, SGPT, "y-GTP, and alkaline phospha- II 
tase levels) between the control subjects and the patients 
~ith liver disease demonstrates the severity of the he-
patic disease in these patients. However, when a com-
parison is made for. these parameters between normal 
subjects and the transplant group, the functional status 
of the transplanted liver is very close to that in the 
normal subjects. Only four patients (Nos. 8, 10, 11, 
and 24) received drugs known to induce (phenytoin or 
phenobarbital), inhibit (cimetidine), or otherwise mod-
ify (levothyroxine) antipyrine kinetics. 
The linear range of the antipyrine standard curve was 
5 to 25 fLg/ml. The coefficients of variation and ac-
curacy were 4.0% and 106%, respectively, at 2.5 fLgl 
ml and 5.3% and 103%, respectively, at 20 fLg/ml 
(n = 10). Antipyrine was found to bind negligibly 
«4%) to the polypropylene tubes used in sample prep-
aration. 
The pharmacokinetic parameters of antipyrine in the 
three groups are listed in Table II, along with the results 
of the statistical comparisons made between the three 
groups. Five patients (Nos. 8 to 12) were studied both 
before and after liver transplantation. Harmonic means 
were calculated for tl/2 and CL and arithmetic means 
were calculated for V lIla.' The harmonic mean tl/2 was 
11.4 hours (range 9.6 to 13.5 hours) for subjects, 25.8 
hours (range 12.1 to 39.2 hours) for patients with liver 
disease, and 10.2 hours (range 6.5 to 14.7 hours) for 
patients after liver transplantation. The harmonic mean 
CL values were 37.9 ml/min (range 27.0 to 50.7 mll 
min) for subjects, 16.7 ml/min (range 12.8 to 28.0 mll 
min) for patients with liver disease, and 36.6 ml/min 
(range 30.6 to 57.4 ml/min) for patients after liver 
transplantation. The antipyrine Az and CL were signif-
icantly smaller (P < 0.05) in the patients with liver 
disease as compared with the subjects and the patients 
after liver transplantation. Varea did not differ signifi- . 
cantly between the three groups. Also, no differences 
were observed in the tl/2 and CL between the control 
and the transplant groups. 
Fig. 1 shows the dramatic decrease in tl/2 in patient 
8 after liver transplantation. In this patient the tl/2 was 
39.2 hours before transplantation and 13.7 hours after 
transplantation. In the five patients who were studied 
before and after transplantation, the mean CL and tl12 
values were 16.6 mlfmin and 28.3 hours before and 
36.0 mlfmin and 12.7 hours after transplantation. There 
\ ) 
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Table II. Antipyrine pharmacokinetics* 
Participant 
No. 
Nonna! subjects 
1 
2 
3 
4 
5 
6 
7 
xt 
10.0 
13.5 
11.8 
10.3 
9.6 
10.9 
10.2 
11.4 
Patients with liver disease 
8 39.2 
9 32.7 
10 16.5 
11 34.8 
12 31.8 
13 12.1 
14 44.0 
15 35.9 
16 38.1 
17 19.8 
x 25.8 
Patients after liver transplantation 
8t 13.7 
9t 11.4 
lOt 11.8 
11+ 10.9 
12:j: 14.7 
18 11.5 
19 6.5 
20 9.9 
21 8.9 
22 11.6 
23 12.9 
24 6.6 
25 10.5 
xt 10.2 
Data are X :: SD. 
mllmin 
43.4 
27.0 
43.8 
50.7 
38.1 
34.8 
37.1 
37.9 
13.9 
16.9 
28.0 
12.8 
16.0 
21.7 
12.8 
15.8 
18.6 
20.3 
16.7 
35.6 
30.6 
34.8 
57.4 
31.1 
31.5 
44.5 
37.2 
38.6 
31.0 
36.9 
54.8 
32.0 
36.6 
*Hannonic mean for tl" and CL: arithmetic mean for sI~K 
tp < 0.05 compared w'ith patients with Jiver disease. 
tAlso studied before transplantation as part of the liver disease group. 
CL 
was a significant increase in CL (P < 0.05) and the Az 
after liver transplantation, but there was no such change 
in V.", •. Table III lists the results of the urinalyses, 
presented as the percentage of dose excreted as un-
changed drug. This information could not be obtained 
in some of the patients because of incomplete urine 
collection or the presence of compounds that interfered 
with the assay procedure. There was no significant dif-
ference between the transplant group and the control 
group in the cumulative amount of antipyrine excreted 
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VOr1!'a 
mllminlkg L Llkg 
0.61 39.6 0.56 
0.53 25.5 0.50 
0.60 44.0 0.61 
0.70 43.4 0.60 
0.62 27.5 0.44 
0.59 36.1 0.61 
0.65 32.8 0.58 
0.61 35.6 :!: 7.3 0.56 :!: 0.06 
0.19 47.1 0.64 
0.23 47.8 0.65 
0.33 40.0 0.47 
0.23 38.7 0.68 
0.34 48.9 0.67 
0.46 22.7 0.48 
0.15 44.0 0.51 
0.22 49.3 0.68 
0.19 61.2 0.61 
0.28 34.8 0.49 
0.24 43.5 :!: 10.3 0.59 :!: 8.09 
0.54 42.1 0.64 
0.47 30.2 0.47 
0.57 35.6 0.63 
1.0 54.1 0.77 
0.44 39.7 0.56 
0.63 32.6 0.65 
0.86 23.5 0.45 
0.65 29.3 0.51 
0.84 29.6 0.64 
0.63 27.9 0.57 
0.42 41.1 0.49 
0.86 31.1 0.49 
0.56 27.2 0.48 
0.61 33.5 :!: 8.9 0.57 :!: 0.1 
in the urine. Compared with values before transplan-
tation, tbe amount of antipyrine excreted unchanged in 
the urine is smaller after transplantation. 
DISCUSSION 
Liver disease in humans results in a variety of patho-
physiologic disturbances that include extra- or intra-
hepatic shunting of blood, hepatocyte dysfunction, 
qualitative and quantitative changes in serum proteins, 
and changes in hepatic blood flow and biliary secretion. 
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Fig. 1. Antipyrine salivary levels before (0) and after (e) liver 
transplantation in patient 8. 
, One of the many end results of such disturbances is the 
. altered disposition of a variety of drugs in patients with 
liver disease. Recently, liver transplantation has be-
come a promising therapeutic option for the treatment 
of certain liver diseases. 3•4 We have used antipyrine as 
a model drug to study the drug metabolizing status of 
the liver in patients with advanced liver disease and in 
patients after liver transplantation. 
Antipyrine has been used extensively as a model drug 
for the assessment of the oxidative metabolizing ca-
pacity of the liver.7 It is an ideal drug for such studies 
because it is completely and rapidly absorbed from the 
gastrointestinal tract, is distributed in total body water 
with negligible binding to tissue or plasma proteins, is 
almost quantitatively metabolized in the liver; 7 and is 
a low-clearance drug with single-compartment kinet-
ics.9 Moreover, the clearance of antipyrine increases 
significantly in patients who receive enzyme-inducing 
agents such as phenytoin 10.11 and is reduced significantly 
in patients with liver disease as well as in patients re-
ceiving drugs that inhibit microsomal enzyme systems 
such as cimetidine. 12•13 
The reported antipyrine arithmetic X (:t SD) CL and 
tl/2 values in normal subjects are 38.4 :t 4.4 ml/min 
and 10.3 :t 0.6 hours. 12 The reported antipyrine CL 
values in patients with liver disease range from 
22.8 :t 3.2 to 10.3 :t 1.6 ml/min and the tl/2 values 
range from 14.5 :t 1.1 to 53.1 hours. 12 Our results in 
normal subjects and in patients with liver disease are 
in agreement with reported values. Whereas antipyrine 
CL was significantly lower in patients with liver disease 
as compared with normal subjects, there was no sig-
nificant difference in Varea between these two groups. 
CLlN PHARMACOL 1RER . 
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Table ill. Percentage of dose administered excreted. 
as unchanged antipyrine in urine 
Patients with liver 
disease 
Patients after 
Control Actual Predicted liver 
subjects values values transplantation 
4.4 5.5 7.8 2.9 
2.2 11.7 15.8 4:3 
4.4 19.9 28.6 7.3 
5.0 7.6 9.9 3.3 
3.2 4.3 6.6 2.8 
2.4 
3.9 
X 3.6* 9.8 13.7 4.1* 
±SD 1.1 6.3 9.0 1.9 
*p < 0.05 compared with patients with liver disease. 
Drug metabolizing actlVlty is therefore significantly 
lower in patients with liver disease than in normal sub-
jects. A comparison of the patients who received liver 
transplant and the control subjects reveals that there 
were no significant differences in the tl/2' CL, and Varea 
values for these two groups. The oxidative metabolizing 
capacity of the patients after liver transplantation, as 
indicated by antipyrine kinetics, appears to be similar 
to that of normal subjects. Therefore, drugs that un-
dergo in vivo metabolism by the same pathways as 
antipyrinel4.IS should behave similarly in normal sub-
jects and in stable patients after liver transplantation. 
Most importantly, after successful liver transplantation 
patients who previously had liver disease eliminate an-
tipyrine in a normal manner; This is apparent from the 
marked increase in antipyrine CL after transplantation 
in these patients. 
Observations based on the salivary data are substan-
tiated by the urinary data. Table ill shows that there 
are no significant differences in the amount of antipy-
rine (as percentage of the dose) excreted unchanged 
between the control and the transplant groups. Because 
antipyrine appears to be metabolized to the same extent 
in these two groups, urinary data suggest that antipyrine 
is being absorbed to the same extent in the transplant 
and the control groups. 
Four of the patients studied were taking drugs that 
could potentially alter antipyrine metabolism. However, 
data analysis that omitted these patients yielded the 
same conclusions as discussed earlier. 
It has recently been reported that steroids inducel6 
while cyclosporine inhibits l7 drug metabolism. In our 
transplant group the oral cyclosporine dosage used 
"' 
1 ,. 
.. l\; .•... 
.,.' 
, ~I 
1 
j 
I 
.1. 
E 
I ;; 
! 
.\' 
t 
I 
VOLUME 39 
/'lUMBER 4 
ranged from 200 to 800 mg b.i.d., while the cyclo-
sporine trough blood levels as measured by RlA ranged 
from 261 to 1731 ng/ml. The prednisone dosage ranged 
from 10 to 20 mg/day. Neither of these two variables 
correlated significantly with antipyrine tl/2 or CL. It is 
possible that the steroids and cyclosporine received by 
these patients might have opposite effects on the CL 
and tl/2 of antipyrine, resulting in the lack of correlation 
observed between these variables and the antipyrine CL 
or t112 • Our results should therefore be interpreted with 
some caution. 
Nonetheless, the patient who has received a liver 
transplant provides a unique model for the examination 
of the effect of liver disease on drug disposition, by 
allowing the study of drug kinetics before and after 
transplantation in the same patient. Our results indicate 
that oxidative drug metabolism in clinically stable pa-
tients after liver transplantation is comparable to that 
found in normal subjects as determined by antipyrine 
pharmacokinetics. We have also shown that liver trans-
plantation improves oxidative metabolism in patients 
with liver disease. 
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